Home>>Infectious Disease>> Bacterial Diseases>> Shigellosis>>C18 Globotriaosylceramide (d18:1/18:0)

C18 Globotriaosylceramide (d18:1/18:0) (Synonyms: C18 Ceramide Trihexoside (d18:1/18:0), Gb3(d18:1/18:0), N-Octadecanoyl-ceramide trihexoside)

Catalog No.GC43049

C18 globotriaosylceramide is an endogenous sphingolipid found in mammalian cell membranes that is synthesized from lactosylceramide.

Products are for research use only. Not for human use. We do not sell to patients.

C18 Globotriaosylceramide (d18:1/18:0) Chemical Structure

Cas No.: 69283-33-6

Size Price Stock Qty
500μg
$848.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

C18 globotriaosylceramide is an endogenous sphingolipid found in mammalian cell membranes that is synthesized from lactosylceramide . It inhibits aggregation of human neutrophils induced by phorbol 12-myristate 13-acetate (PMA; 10008014) when used at a concentration of 1 μM. C18 globotriaosylceramide acts as a receptor for Shiga toxin in B cell-derived Raji cells and THP-1 monocytes. It accumulates in the brain, heart, kidney, liver, lung, and spleen in a mouse model of Fabry disease, a lysosomal storage disorder characterized by a deficiency in the enzyme α-galactosidase A. C18 globotriaosylceramide also accumulates in endothelial cells, pericytes, vascular smooth muscle cells, renal epithelial cells, dorsal ganglia neuronal cells, and myocardial cells in patients with Fabry disease.

Reviews

Review for C18 Globotriaosylceramide (d18:1/18:0)

Average Rating: 5 ★★★★★ (Based on Reviews and 25 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for C18 Globotriaosylceramide (d18:1/18:0)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.